Arbutus Biopharma Corp (ABUS) stock
ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 12/3082% below fair value
$3.88+0.06 (+1.57%)
Close on Nov 11, 2026Market cap $767.65MP/E 3.5Yield –
Arbutus Biopharma r&d expenses
Research and development expenses are spending on new products and technology.
Arbutus Biopharma's R&D Expenses for the twelve months ending Sep 30, 2026 was $14.64M, down 49.6% year over year. For fiscal 2025 it was $25.24M, down 53.3% from the year before. Over ten years it grew -6.9% a year on average. The highest annual figure on record is $84.41M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.24M | -53.3% |
| FY2024 | Dec 31, 2024 | $54.04M | -26.7% |
| FY2023 | Dec 31, 2023 | $73.70M | -12.7% |
| FY2022 | Dec 31, 2022 | $84.41M | +28.9% |
| FY2021 | Dec 31, 2021 | $65.50M | +32.8% |
| FY2020 | Dec 31, 2020 | $49.34M | -14.3% |
| FY2019 | Dec 31, 2019 | $57.60M | -0.6% |
| FY2018 | Dec 31, 2018 | $57.93M | -7.6% |
| FY2017 | Dec 31, 2017 | $62.68M | +2.3% |
| FY2016 | Dec 31, 2016 | $61.25M | +18.9% |
| FY2015 | Dec 31, 2015 | $51.51M | +33.0% |
| FY2014 | Dec 31, 2014 | $38.71M | +80.4% |
| FY2013 | Dec 31, 2013 | $21.46M | +18.9% |
| FY2012 | Dec 31, 2012 | $18.04M | -10.4% |
| FY2011 | Dec 31, 2011 | $20.13M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.62M | -54.7% |
| Q2 FY2026 | Jun 30, 2026 | $2.90M | -47.3% |
| Q1 FY2026 | Mar 31, 2026 | $4.12M | -54.0% |
| Q4 FY2025 | Dec 31, 2025 | $5.01M | -43.2% |
| Q3 FY2025 | Sep 30, 2025 | $5.78M | -59.5% |
| Q2 FY2025 | Jun 30, 2025 | $5.50M | -64.6% |
| Q1 FY2025 | Mar 31, 2025 | $8.96M | -41.8% |
| Q4 FY2024 | Dec 31, 2024 | $8.81M | -49.8% |
| Q3 FY2024 | Sep 30, 2024 | $14.27M | -29.2% |
| Q2 FY2024 | Jun 30, 2024 | $15.55M | -12.1% |
| Q1 FY2024 | Mar 31, 2024 | $15.40M | -15.7% |
| Q4 FY2023 | Dec 31, 2023 | $17.56M | -23.5% |
| Q3 FY2023 | Sep 30, 2023 | $20.17M | +0.6% |
| Q2 FY2023 | Jun 30, 2023 | $17.69M | -22.9% |
| Q1 FY2023 | Mar 31, 2023 | $18.28M | -1.0% |
| Q4 FY2022 | Dec 31, 2022 | $22.95M | +19.5% |
| Q3 FY2022 | Sep 30, 2022 | $20.06M | +20.0% |
| Q2 FY2022 | Jun 30, 2022 | $22.94M | +45.2% |
| Q1 FY2022 | Mar 31, 2022 | $18.46M | +34.0% |
| Q4 FY2021 | Dec 31, 2021 | $19.21M | +17.2% |
| Q3 FY2021 | Sep 30, 2021 | $16.71M | +38.5% |
| Q2 FY2021 | Jun 30, 2021 | $15.80M | +51.0% |
| Q1 FY2021 | Mar 31, 2021 | $13.78M | +32.3% |
| Q4 FY2020 | Dec 31, 2020 | $16.39M | +32.0% |
| Q3 FY2020 | Sep 30, 2020 | $12.07M | -32.0% |
| Q2 FY2020 | Jun 30, 2020 | $10.47M | -17.9% |
| Q1 FY2020 | Mar 31, 2020 | $10.42M | -29.2% |
| Q4 FY2019 | Dec 31, 2019 | $12.42M | +12.2% |
| Q3 FY2019 | Sep 30, 2019 | $17.73M | +7.0% |
| Q2 FY2019 | Jun 30, 2019 | $12.74M | -22.1% |
| Q1 FY2019 | Mar 31, 2019 | $14.71M | +5.5% |
| Q4 FY2018 | Dec 31, 2018 | $11.06M | -37.9% |
| Q3 FY2018 | Sep 30, 2018 | $16.57M | +6.6% |
| Q2 FY2018 | Jun 30, 2018 | $16.36M | +5.9% |
| Q1 FY2018 | Mar 31, 2018 | $13.95M | +0.6% |
| Q4 FY2017 | Dec 31, 2017 | $17.82M | +3.9% |
| Q3 FY2017 | Sep 30, 2017 | $15.54M | – |
| Q2 FY2017 | Jun 30, 2017 | $15.45M | – |
| Q1 FY2017 | Mar 31, 2017 | $13.87M | – |
| Q4 FY2016 | Dec 31, 2016 | $17.16M | – |
See a number that looks wrong?